Monte Rosa Therapeutics, INC 8-K filings

Monte Rosa Therapeutics reported strong Q2 2026 progress with key clinical trial activations and enrollment completions, alongside a robust cash runway extending into 2029, though net loss widened.

Monte Rosa Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of three Class II directors and the ratification of its independent auditor.

Monte Rosa Therapeutics reported Q1 2026 results, highlighting significant clinical program advancements and a strong cash position expected to fund operations into 2029.

Monte Rosa Therapeutics announced positive clinical data for multiple programs, strengthened its balance sheet with a $345 million financing, and extended its cash runway into 2029.

Monte Rosa Therapeutics announces the retirement of its SVP, Corporate Controller, and Principal Accounting Officer, Edmund Dunn, and the appointment of Matthew Bowen as his successor.

Monte Rosa Therapeutics announced the pricing of an underwritten public offering of common stock and pre-funded warrants, expecting to raise approximately $281.6 million in net proceeds to fund its pipeline and platform development.

Monte Rosa Therapeutics, Inc. has terminated its at-the-market sales agreement prospectus, halting further common stock sales under the current facility.

Monte Rosa Therapeutics announced positive interim Phase 1 data for MRT-8102, demonstrating significant CRP reductions and a favorable safety profile in subjects with elevated cardiovascular disease risk.

Monte Rosa Therapeutics announced compelling interim Phase 1/2 clinical data for MRT-2359 in combination with enzalutamide for heavily pretreated metastatic castration-resistant prostate cancer patients with AR mutations.

Monte Rosa Therapeutics announced a new $120 million upfront payment from Novartis, strong Q3 2025 financial results, and significant progress across its clinical-stage molecular glue degrader programs.

Monte Rosa Therapeutics announced a collaboration with Novartis for up to $5.7 billion to discover and develop degraders for immune-mediated diseases.

Monte Rosa Therapeutics announced strong second quarter 2025 financial results, significantly reducing net loss while advancing its molecular glue degrader pipeline with multiple programs progressing towards key clinical milestones.

Monte Rosa Therapeutics, Inc. announced the successful election of three Class I directors and the ratification of Deloitte & Touche LLP as its independent registered public accounting firm at its 2025 Annual Meeting of Stockholders.

Monte Rosa Therapeutics announced encouraging Q1 2025 financial results and provided updates on its advancing pipeline of molecular glue degrader (MGD)-based medicines.

Monte Rosa Therapeutics reports encouraging clinical results from MRT-6160 and MRT-2359 programs, along with a strong cash position expected to fund operations into 2028.

Monte Rosa Therapeutics anticipates multiple clinical data readouts and advancement of its pipeline programs in 2025, supported by a strong cash position.

Monte Rosa Therapeutics has appointed Dr. Eric A. Hughes, a seasoned pharmaceutical executive, to its Board of Directors, effective December 11, 2024.

Monte Rosa Therapeutics reports favorable safety and pharmacodynamic results from its Phase 1/2 study of MRT-2359, a GSPT1 degrader, in patients with MYC-driven solid tumors, selecting a recommended Phase 2 dose.

Monte Rosa Therapeutics announced a global licensing agreement with Novartis for its VAV1-directed molecular glue degraders, securing a $150 million upfront payment and up to $2.1 billion in potential milestones.

Monte Rosa Therapeutics has entered into a global licensing agreement with Novartis for its VAV1 molecular glue degraders, including MRT-6160, potentially worth up to $2.25 billion.

Monte Rosa Therapeutics reported its second quarter 2024 financial results, highlighted by IND clearance for MRT-6160 and progress in multiple clinical programs.

Monte Rosa Therapeutics reports encouraging safety and pharmacodynamic data for its cancer drug MRT-2359 and has submitted an IND for its autoimmune disease drug MRT-6160.

Monte Rosa Therapeutics held its 2024 Annual Meeting of Stockholders, electing two Class III directors and ratifying the appointment of Deloitte & Touche LLP as its independent auditor for the fiscal year ending December 31, 2024.

Monte Rosa Therapeutics has promoted three key executives, including Jennifer Champoux to Chief Operating Officer, to strengthen its leadership team and advance its drug development programs.

Monte Rosa Therapeutics has announced the pricing of a $100 million public offering of common stock and pre-funded warrants to fund clinical development and general corporate purposes.

Monte Rosa Therapeutics announced its first quarter 2024 financial results and provided a corporate update, highlighting progress in its molecular glue degrader programs.

Monte Rosa Therapeutics' Chief Scientific Officer, Owen Wallace, Ph.D., has resigned effective May 17, 2024, to become CEO of a UK-based biotech company, and will transition to a scientific advisory role with Monte Rosa.

Monte Rosa Therapeutics announced its full year 2023 financial results and provided updates on its clinical and preclinical programs, including the advancement of MRT-2359, MRT-6160, and MRT-8102.